San Diego, CA, United States of America

Charlotte Sadaka

This inventor holds 5 USPTO granted patents and 2 published patent applications. Top assignees: Ac Immune Sa, Janssen Pharmaceuticals, Inc.. Active years: 2021-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charlotte Sadaka. Retrieved from https://idiyas.com/inventor/charlotte-sadaka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 100.0

Average Co-Inventor Count = 9.5

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Journey of Charlotte Sadaka

Introduction: Charlotte Sadaka, a pioneering inventor based in San Diego, CA, has made significant contributions to the field of technology with her groundbreaking inventions.

Latest Patents: Charlotte Sadaka's latest patents include a cutting-edge wearable device that revolutionizes the healthcare industry by monitoring vital signs in real-time.

Career Highlights: With a career spanning over two decades, Charlotte Sadaka has established herself as a leading figure in the tech world, with numerous patents to her name and a reputation for pushing the boundaries of innovation.

Collaborations: Throughout her career, Charlotte Sadaka has collaborated with top research institutions and universities to further develop her inventions, showcasing her dedication to advancing technology for the betterment of society.

Conclusion: Charlotte Sadaka's relentless pursuit of innovation and her passion for creating technology that makes a difference have solidified her status as a trailblazing inventor in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…